Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of cancer treatments, and can result in long-term functional disability and reduced quality of life. However, the impact of CIPN on cancer survivors is poorly understood. Our aim is to investigate the impact of neurotoxic chemotherapy side effects on the health, physical activity, and quality of life of Australian cancer survivors. An anonymous online survey platform was developed addressing demographics, cancer diagnosis and treatment, the experience of CIPN and other side effects of chemotherapy, and included standardised measures to assess general health, quality of life, physical activity, neuropathy symptoms and pain. Analysis of 411 respondents (87% female; 13% male) with a median age of 58 years revealed a majority of patients treated for breast cancer (68%), with 10% of participants treated for multiple myeloma, 8% for colorectal cancer and 5% for ovarian cancer. The majority of respondents (78%) were currently experiencing neuropathic symptoms in the hands or feet. Greater severity of symptoms was reported in the feet – with 22% reporting ‘very much’ numbness or tingling compared to 11% for hands. In the 3.3 ± 0.1 years since completion of chemotherapy treatment (range 0-20 years), 28% respondents reported no improvement in symptoms. Accordingly, 51% of participants reported functional impact of CIPN on walking ability, 41% of participants reported impact on hand function and 58% indicated that they were limited in conducting vigorous physical activity. Neuropathy was rated as the cancer treatment side effect with the second greatest impact on participants’ lives after fatigue, with 22% of participants reporting neuropathy as having the biggest impact on their lives. These findings indicate that CIPN has a lasting impact on cancer survivors and further work is required to establish best practice assessment, prevention and treatment approaches.